AstraZeneca’s COVID-19 antibody jab approved for adults medically unsuitable for vaccination: HSA
SINGAPORE: The Health Sciences Authority (HSA) on Monday (Aug 1) granted interim authorisation for AstraZeneca's COVID-19 antibody drug for adults who are medically unsuitable for vaccination against the coronavirus.
The Evusheld treatment comprises two monoclonal antibodies and is administered via intramuscular injection.
HSA said the treatment is approved for the prevention of COVID-19 in adults who have not had a known recent exposure to someone infected with the disease and are unlikely to mount an adequate immune response to COVID-19 vaccination.
This may be due to their immunocompromised state from a medical condition or from receiving immunosuppressive medications or treatments.
Such medical conditions or treatments include those who are in an immunocompromised state from organ,...









